Corcept Therapeutics (CORT) Tops Q3 EPS by 3c

November 1, 2016 5:52 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $21.7 million versus the consensus estimate of $21.24 million.


Corcept Therapeutics sees Q4 2016 revenue of $79-82 million, versus the consensus of $80.3 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment